Immunopathogenesis of Hidradenitis Suppurativa: Updated Review
DOI:
https://doi.org/10.12775/JEHS.2026.87.67658Keywords
hidradenitis suppurativa, immunopathogenesis, immunology, complement activation, T-cell responsesAbstract
Introduction and Objective. Hidradenitis suppurativa (HS) is a chronic, recurrent inflammatory skin disease characterized by follicular occlusion, painful nodules, abscesses, sinus tract formation, and scarring, primarily affecting intertriginous areas. Although previously considered a disorder of the apocrine glands, HS is now recognized as a complex immunoinflammatory condition involving dysregulation of innate and adaptive immune pathways. This review aims to summarize current knowledge on the immunopathogenesis of HS, with particular emphasis on recent molecular and cellular insights relevant to targeted therapy.
Brief Overview of Current Knowledge. The initiating event in HS is follicular hyperkeratosis, leading to follicular rupture and secondary inflammation. Disease progression is driven by persistent immune activation, dominated by Th1/Th17 polarization. Key mechanisms include increased expression of proinflammatory cytokines such as IL-17, IL-1β, TNF-α, and IFN-γ, activation of the complement system, especially C5a, and dysregulation of antimicrobial peptides. Aberrant interactions between keratinocytes, fibroblasts, plasma cells, innate lymphoid cells, and T-cell subsets contribute to chronic inflammation and tissue destruction.
Summary. Hidradenitis suppurativa is a multifactorial immunoinflammatory disease in which follicular occlusion initiates a complex immune cascade. Identification of biomarkers and therapeutic targets, including IL-17-driven pathways, complement components, and CD2–CD58 signaling, supports the development of personalized, mechanism-based treatment strategies. Improved understanding of HS immunopathogenesis may enhance disease stratification and clinical outcomes.
References
1. Ballard K, Sathe NC, Shuman VL. Hidradenitis Suppurativa. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan– [Updated 6 May 2024]. Bookshelf ID: NBK534867.
2. Vinkel C, Thomsen SF. Hidradenitis Suppurativa: Causes, Features, and Current Treatments. J Clin Aesthet Dermatol. 2018 Oct;11(10):17-23. Epub 2018 Oct 1.
3. Kokolakis G, Wolk K, Schneider-Burrus S, Kalus S, Barbus S, Gomis-Kleindienst S, Sabat R. Delayed Diagnosis of Hidradenitis Suppurativa and Its Effect on Patients and Healthcare System. Dermatology. 2020;236(5):421-430. doi: 10.1159/000508787. Epub 2020 Jul 1.
4. Chernyshov PV, Finlay AY, Tomas-Aragones L, Poot F, Sampogna F, Marron SE, Zemskov SV, Abeni D, Tzellos T, Szepietowski JC, Zouboulis CC. Quality of Life in Hidradenitis Suppurativa: An Update. Int J Environ Res Public Health. 2021 Jun 6;18(11):6131. doi: 10.3390/ijerph18116131.
5. Zouboulis CC, Bechara FG, Dickinson-Blok JL, Gulliver W, Horváth B, Hughes R, Kimball AB, Kirby B, Martorell A, Podda M, Prens EP, Ring HC, Tzellos T, van der Zee HH, van Straalen KR, Vossen ARJV, Jemec GBE. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol. 2019 Jan;33(1):19-31. doi: 10.1111/jdv.15233. Epub 2018 Oct 23.
6. van Straalen KR, Prens EP, Gudjonsson JE. Insights into hidradenitis suppurativa. J Allergy Clin Immunol. 2022;149(6):1892–1905. doi:10.1016/j.jaci.2022.02.003.
7. Garg A, Malviya N, Strunk A, Wright S, Alavi A, Alhusayen R, Alikhan A, Daveluy SD, Delorme I, Goldfarb N, Gulliver W, Hamzavi I, Jaleel T, Kimball AB, Kirby JS, Kirchhof MG, Lester J, Lev-Tov H, Lowes MA, Micheletti R, Orenstein LA, Piguet V, Sayed C, Tan J, Naik HB. Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations. J Am Acad Dermatol. 2022 May;86(5):1092-1101. doi: 10.1016/j.jaad.2021.01.059. Epub 2021 Jan 23.
8. Vinding GR, Bhuiyan MSI. Global Prevalence of Hidradenitis Suppurativa. Dermatology. 2025;241(Suppl 1):7-8. doi:10.1159/000542381.
9. Phan K, Charlton O, Smith SD. Global prevalence of hidradenitis suppurativa and geographical variation—systematic review and meta-analysis. Biomed Dermatol. 2020;4:2. doi:10.1186/s41702-019-0052-0.
10. Alotaibi HM. Incidence, Risk Factors, and Prognosis of Hidradenitis Suppurativa Across the Globe: Insights from the Literature. Clin Cosmet Investig Dermatol. 2023 Mar 2;16:545-552. doi: 10.2147/CCID.S402453.
11. Almenara-Blasco M, Gracia-Cazaña T, Poblador-Plou B, Laguna-Berna C, Navarro-Bielsa A, Moreno-Juste A, Gimeno-Miguel A, Gilaberte Y. Multimorbidity of hidradenitis suppurativa: a cross-sectional population-based study of its associated comorbidities. Front Med (Lausanne). 2025 Sep 5;12:1618975. doi: 10.3389/fmed.2025.1618975.
12. Jfri A, Nassim D, O'Brien E, Gulliver W, Nikolakis G, Zouboulis CC. Prevalence of Hidradenitis Suppurativa: A Systematic Review and Meta-regression Analysis. JAMA Dermatol. 2021 Aug 1;157(8):924-931. doi: 10.1001/jamadermatol.2021.1677.
13. Medianfar CE, Medianfar CE, Fernandez LI, Bouazzi D, Jemec GBE. Global Hidradenitis Suppurativa Epidemiology: Exploring Themes and Gaps beyond Europe, Australia, and the USA. Dermatology. 2025;241(Suppl. 1):159-170. doi: 10.1159/000542389. Epub 2025 Jul 7.
14. Knecht-Gurwin K, Gurwin A, Wróbel T, Bouazzi D, Medianfar CE, Christensen R, Jemec GBE, Szepietowski JC, Matusiak Ł. Prevalence of Hidradenitis Suppurativa in Poland. Dermatology. 2025;241(Suppl 1):98-106. doi:10.1159/000541951.
15. Matusiak Ł, Kaszuba A, Krasowska D, Placek W, Szepietowski J. Epidemiology of hidradenitis suppurativa in Poland in relation to international data. Dermatology Review/Przegląd Dermatologiczny. 2017;104(4):377-384. doi:10.5114/dr.2017.69945.
16. Vossen ARJV, van der Zee HH, Prens EP. Hidradenitis Suppurativa: A Systematic Review Integrating Inflammatory Pathways Into a Cohesive Pathogenic Model. Front Immunol. 2018 Dec 14;9:2965. doi:10.3389/fimmu.2018.02965.
17. McCarthy S. Hidradenitis Suppurativa. Annu Rev Med. 2025 Jan;76(1):69-80. doi: 10.1146/annurev-med-051223-031234. PMID: 39869430.
18. Burke OM, Frerichs VR, Garcia DF, Stone RC, Lev-Tov H, Czarnowicki T, Keane RW, Ojeh N, Marjanovic J, Pastar I, Tomic-Canic M, de Rivero Vaccari JP, Sawaya AP. The impact of innate immunity and epigenetics in the pathogenesis of hidradenitis suppurativa. Front Immunol. 2025 May 19;16:1593253. doi:10.3389/fimmu.2025.1593253.
19. Sabat R, Alavi A, Wolk K, Wortsman X, McGrath B, Garg A, Szepietowski JC. Hidradenitis suppurativa. Lancet. 2025 Feb 1;405(10476):420-438. doi: 10.1016/S0140-6736(24)02475-9. Epub 2025 Jan 22.
20. Scala E, Cacciapuoti S, Garzorz-Stark N, Megna M, Marasca C, Seiringer P, Volz T, Eyerich K, Fabbrocini G. Hidradenitis Suppurativa: Where We Are and Where We Are Going. Cells. 2021 Aug 15;10(8):2094. doi: 10.3390/cells10082094.
21. Lee EY, Alhusayen R, Lansang P, Shear N, Yeung J. What is hidradenitis suppurativa? Can Fam Physician. 2017 Feb;63(2):114-120.
22. Wieczorek M, Walecka I. Hidradenitis suppurativa - known and unknown disease. Reumatologia. 2018;56(6):337-339. doi: 10.5114/reum.2018.80709. Epub 2018 Dec 23.
23. Vekic DA, Cains GD. Hidradenitis suppurativa - Management, comorbidities and monitoring. Aust Fam Physician. 2017;46(8):584-588. 23.
24. Diaz MJ, Aflatooni S, Abdi P, Li R, Anthony MR, Neelam S, Farkouh C, Tran JT, Svoboda S, Forouzandeh M, Valdes Rodriguez RH. Hidradenitis Suppurativa: Molecular Etiology, Pathophysiology, and Management-A Systematic Review. Curr Issues Mol Biol. 2023 May 17;45(5):4400-4415. doi: 10.3390/cimb45050280.
25. Tricarico PM, Gratton R, Dos Santos-Silva CA, de Moura RR, Ura B, Sommella E, Campiglia P, Del Vecchio C, Moltrasio C, Berti I, D'Adamo AP, Elsherbini AMA, Staudenmaier L, Chersi K, Boniotto M, Krismer B, Schittek B, Crovella S. A rare loss-of-function genetic mutation suggest a role of dermcidin deficiency in hidradenitis suppurativa pathogenesis. Front Immunol. 2022 Dec 5;13:1060547. doi: 10.3389/fimmu.2022.1060547.
26. Schmitt JV, Bombonatto G, Martin M, Miot HA. Risk factors for hidradenitis suppurativa: a pilot study. An Bras Dermatol. 2012 Nov-Dec;87(6):936-8. doi: 10.1590/s0365-05962012000600024.
27. Benzecry V, Grancini A, Guanziroli E, Nazzaro G, Barbareschi M, Marzano AV, Muratori S, Veraldi S. Hidradenitis suppurativa/acne inversa: a prospective bacteriological study and review of the literature. G Ital Dermatol Venereol. 2020 Aug;155(4):459-463. doi: 10.23736/S0392-0488.18.05875-3. Epub 2018 Apr 19.
28. Scheinfeld N. Hidradenitis suppurativa: A practical review of possible medical treatments based on over 350 hidradenitis patients. Dermatol Online J. 2013 Apr 15;19(4):1.
29. Agnese ER, Tariche N, Sharma A, Gulati R. The Pathogenesis and Treatment of Hidradenitis Suppurativa. Cureus. 2023 Nov 25;15(11):e49390. doi: 10.7759/cureus.49390.
30. Gudjonsson JE, Tsoi LC, Ma F, Billi AC, van Straalen KR, Vossen ARJV, van der Zee HH, Harms PW, Wasikowski R, Yee CM, Rizvi SM, Xing X, Xing E, Plazyo O, Zeng C, Patrick MT, Lowe MM, Burney RE, Kozlow JH, Cherry-Bukowiec JR, Jiang Y, Kirma J, Weidinger S, Cushing KC, Rosenblum MD, Berthier C, MacLeod AS, Voorhees JJ, Wen F, Kahlenberg JM, Maverakis E, Modlin RL, Prens EP. Contribution of plasma cells and B cells to hidradenitis suppurativa pathogenesis. JCI Insight. 2020 Oct 2;5(19):e139930. doi: 10.1172/jci.insight.139930.
31. Frew JW. Unravelling the complex pathogenesis of hidradenitis suppurativa. Br J Dermatol. 2025 Feb 3;192(Supplement_1):i3-i14. doi: 10.1093/bjd/ljae238.
32. Yao Y, Thomsen SF. The role of interleukin-17 in the pathogenesis of hidradenitis suppurativa. Dermatol Online J. 2017 Jul 15;23(7):13030/qt8rw2j9zv.
33. Thomi R, Cazzaniga S, Seyed Jafari SM, Schlapbach C, Hunger RE. Association of Hidradenitis Suppurativa With T Helper 1/T Helper 17 Phenotypes: A Semantic Map Analysis. JAMA Dermatol. 2018 May 1;154(5):592-595. doi: 10.1001/jamadermatol.2018.0141.
34. Kanni T, Zenker O, Habel M, Riedemann N, Giamarellos-Bourboulis EJ. Complement activation in hidradenitis suppurativa: a new pathway of pathogenesis? Br J Dermatol. 2018 Aug;179(2):413-419. doi: 10.1111/bjd.16428. Epub 2018 May 10.
35. Kashyap MP, Mishra B, Sinha R, Jin L, Gou Y, Kumar N, Goliwas KF, Haque S, Deshane J, Berglund E, Berglund D, Elewski BE, Elmets CA, Athar M, Mukhtar MS, Raman C. CD2 expressing innate lymphoid and T cells are critical effectors of immunopathogenesis in hidradenitis suppurativa. Proc Natl Acad Sci U S A. 2024 Nov 26;121(48):e2409274121. doi: 10.1073/pnas.2409274121. Epub 2024 Nov 19.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Wiktoria Marszał, Sandra Czyż, Nina Saracen

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 22
Number of citations: 0